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Abstract
Background: The dysfunction of vascular endothelium precedes the development of atherosclero-
sis in patients with arterial hypertension. Nebivolol is a very specific beta-blocker, which can be
characterized by a strong endothelial vasodilatative effect. The aim of the study was the assessment
of changes in concentrations of serum nitric oxide (NO), plasma von Willebrand factor (vWf) and
selected parameters of electrocardiographic exercise tests after 4-week nebivolol treatment.
Methods: Twenty-one patients were included in the study, aged from 34 to 82 years with
primary arterial hypertension or primary arterial hypertension and ischemic heart disease.
Blood samples were taken for measurements of serum NO and plasma vWf. Electrocardio-
graphic stress tests were also performed. Subsequently, nebivolol was administered for four
weeks and the aforementioned measurements were repeated.
Results: A significant increase in serum NO concentration was found in all the investigated
patients after nebivolol treatment. A prolongation of exercise time, increase in metabolic equiva-
lent and decrease in double product were also noted in patients after nebivolol treatment.
Conclusions: Nebivolol treatment improves parameters of electrocardiographic exercise test
in patients with arterial hypertension. The improvement of the parameters of the exercise test
was not observed in those patients who showed no significant increase in serum NO concen-
tration following nebivolol treatment. (Cardiol J 2008; 15: 162–168)
Key words: nebivolol, nitric oxide, von Willebrand factor, arterial hypertension,
ischemic heart disease
Introduction
The dysfunction of vascular endothelium pre-
cedes the development of atherosclerosis in pa-
tients with arterial hypertension. The prevention
of endothelial damage may potentially delay the
appearance of atherosclerotic plaques in blood ves-
sels. It can be assumed that reparative processes,
which allow vascular endothelium to regain its lost
functional integrity, should slow down the progres-
sion of atherosclerotic processes.
Nebivolol is a beta-blocker with very special
qualities [1]. It has the highest cardiac beta-recep-
tor selectivity among all beta-blockers and a strong
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endothelial nitric oxide-mediated vasodilatative ef-
fect. It has been confirmed that endothelial function-
dependent vasodilation becomes ameliorated in
hypertensive patients receiving nebivolol treat-
ment. Tzemos et al. [2] demonstrated the additio-
nal vasoprotective effects of nebivolol as compared
with atenolol. Nebivolol increased both stimulated
and basal endothelial nitric oxide release, where-
as, for the same degree of blood pressure control,
atenolol had no effect on nitric oxide (NO) bioactivi-
ty. The vasodilatory response to acetylcholine was
significantly increased with nebivolol, but not with
atenolol. Concomitantly, the endothelium-dependent
vasoconstrictive response to N(G)-monomethyl-L-
-arginine (L-NMMA) was significantly reduced,
which again was not demonstrated with atenolol [2].
Brehm et al. [3] also demonstrated that nebi-
volol inhibits the proliferation of human coronary
smooth muscle cells induced by growth factors,
whereas classical beta-blockers do not affect cell
growth. During incubation of endothelial cells
(HaECs) with nebivolol, NO formation of HaECs in-
creased, while endothelin-1 transcription and secre-
tion were suppressed. The previous nebivolol in-
vestigations demonstrated both vasodilating pro-
perties of nebivolol and significant mortality
reduction in patients treated with this unique beta-
blocker [4].
The plasma von Willebrand factor, regarded as
a very good indicator of endothelial dysfunction,
contributes to the activation of the coagulation ca-
scade [5, 6]. An increased plasma concentration of
von Willebrand factor was found in patients suffe-
ring from various cardiovascular diseases. The pro-
spective studies demonstrated that the increased
plasma concentration of this coagulation factor was
strongly related to poor prognosis in cardiovascu-
lar patients, an increased number of major vascular
events (myocardial infarction, brain stroke) and high
mortality rate [7].
The aim of the study was the assessment of the
dynamics of changes in concentrations of serum
nitric oxide, plasma von Willebrand factor and the
selected parameters of electrocardiographic tread-
mill tests after one month of nebivolol treatment
in hypertensive patients with chronic ischemic he-
art disease.
Methods
Twenty-one patients aged from 34 to 82 years
(mean age 59.3 ± 12.2 years; 15 females and
6 males) with primary arterial hypertension or pri-
mary arterial hypertension and ischemic heart di-
sease, untreated before with beta-blockers, ente-
red the study. The diagnosis of ischemic heart di-
sease was confirmed in the investigated patients
after considering the typical clinical symptoms, the
presence of myocardial ischemia during electrocar-
diographic stress test and the outcome of coronary
arteriography. The patients affected with renal or
hepatic failure, systemic connective tissue diseases,
cancer, or acute or chronic inflammatory diseases
were excluded from the study.
The investigated patients were divided into two
groups:
— group 1 — 11 patients (mean age 56.6 ± 10.9
years) with arterial hypertension of moderate
degree according to the European Society of
Cardiology (ESC) classification;
— group 2 — 10 patients (mean age 62.3 ± 10.6
years) with arterial hypertension of moderate
degree according to ESC classification and
ischemic heart disease in stage II according to
Canadian Cardiac Society (CCS).
Depending on changes in serum NO concen-
tration after nebivolol treatment, two subgroups of
patients were established:
— group 3 — 11 patients (mean age 64 ± 13.0
years) — increase in serum NO concentration
was observed;
— group 4 — 10 patients (mean age 62.6 ± 9.7
years) — increase in serum NO concentration
was not observed.
Blood samples were taken in the morning ho-
urs from the decubital vein in all the study patients
for measurements of concentrations of serum NO,
plasma von Willebrand factor and blood lipids. Sub-
sequently, echocardiographic interrogations and
electrocardiographic (ECG) stress tests were also
performed. Afterwards, nebivolol in a dose of 5 mg
per day (Nebilet, Berlin-Chemie Company) was
orally administered to all the examined patients
according to the 4-week follow-up protocol. The
afore-mentioned biochemical measurements and
ECG stress tests were performed again after the
4-week nebivolol treatment. All patients underwent
electrocardiographic stress tests according to Bru-
ce protocol (Burdick T 600 computerized system
combined with ECG apparatus, Sicard 460 S — Sie-
mens company). The following criteria of exercise
test termination were accepted for the investiga-
tion protocol: 1) examined patient reached age-li-
mited increase in MET (metabolic equivalent) and/
/or submaximal heart rate; 2) presence of myocardial
ischemia in ECG tracings; 3) acute anginal chest pain;
4) wishes of a patient — symptoms of fatigue. After-
wards, the following ECG stress test parameters were
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evaluated: time of exercise, MET, degree of ST de-
pression and double product (heart rate multiplied by
systolic blood pressure during peak exercise).
Echocardiographic interrogation was perfor-
med in every patient using Wingmed LG apparatus
with a 3.5 MHz transducer. The left ventricular
ejection fraction was determined using biplane
Simpson’s rule.
The concentration of plasma von Willebrand
factor was measured with ELISA immunoassay
using Asserachrom vWf:Ag kit. The blood samples
were placed into test tubes with a 3.2% solution of
sodium citrate and then centrifuged for 15 min at
2500 revolutions per minute (rpm). Afterwards, the
obtained plasma was stored at –70°C. The intra- and
interassay variability was below 5%.
The serum NO concentration was measured
with spectrophotometry using R&D Systems’
Total Nitric Oxide Assay kit, catalogue number
DE 1600. The blood samples were centrifuged for
10 min at 1000 rpm. Afterwards, the obtained pla-
sma was stored at –70°C. The measurements of
plasma NO concentration were made by using trans-
formation of NO into nitrate (III) and nitrate (V)
catalyzed by nitrate reductase. The total transfor-
med nitrate (III) was then detected spectrophoto-
metrically using the Griess reaction. The intra- and
interassay variability was below 5%.
The study was approved by the local ethical
committee and all patients gave their informed con-
sent.
Statistical anaylysis
Statistical analysis was performed using STA-
TISTICA 5.0. Means and standard deviations were
calculated for the selected parameters. Normal di-
stribution of data was tested by the Shapiro-Wilk
test. The non-parametric U-Mann-Whitney and
Kruskal-Wallis tests were applied when the normal
distribution of data was not confirmed. If the nor-
mal distribution of data was confirmed, further ana-
lysis was performed by means of Student’s t-test
for paired and unpaired samples. The highest relia-
bility c² test with Yates’ correction and Fisher’s
exact test were used when the statistical significan-
ce of quantitative changes in the examined parame-
ters was tested. The correlations between investi-
gated parameters were assessed using Pearson’s
linear coefficient and the non-parametric Spear-
man’s coefficient. Statistical significance was con-
sidered at p < 0.05
Results
Significantly lower serum NO concentrations
were found in all the examined patients, compared
with healthy volunteers before the start of the in-
vestigation (12.3 ± 4.7 µM vs. 19.6 ± 6.1 µM;
p < 0.02). The von Willebrand factor levels in the
study group were not significantly different from
those of the control group (105.5 ± 21.9% vs. 98.15 ±
± 34.7%).
A significant increase in serum NO concentra-
tions was found in all the investigated patients after
nebivolol treatment. However, serum NO levels
were still much lower than those of the control gro-
up (Table 1). Significant changes in von Willebrand
factor levels were not observed during the investi-
gation period.
A significant increase in serum NO concen-
tration was found after nebivolol treatment in pa-
tients from groups 1 and 2. However, no signifi-
cant changes in von Willebrand factor concentra-
tions were observed (Table 2). A very high
increase in serum NO concentration was obse-
rved in group 2. After 4-week nebivolol treat-
ment, the serum NO levels were comparable to
those of the control group. The NO and von
Table 1. Concentration of serum nitric oxide, plasma von Willebrand factor, blood lipids and left ventricular
ejection fraction in all investigated patients with arterial hypertension and ischemic heart disease.
Parameter Before nebivolol After nebivolol Statistical
treatment  treatment  significance
von Willebrand factor (%) 105.5 ± 21.9 124.4 ± 48.3 NS
Nitric oxide [ng/ml] 12.3 ± 4.7 15.4 ± 5.9 < 0.05
Total cholesterol [mg%] 216.6 ± 36.7 193.7 ± 49.9 NS
Cholesterol LDL [mg%] 129.3 ± 29.7 120.9 ± 52.6 NS
Cholesterol HDL [mg%] 58.1 ± 19.4 54.7 ± 15.9 NS
Triglycerides [mg%] 115.1 ± 50.0 103.0 ± 23.8 NS
Left ventricular ejection fraction (%) 71.0 ± 5.8 64.3 ± 20.9 NS
NS — non-significant
165
Małgorzata Kobusiak-Prokopowicz et al., Impact of nebivolol on NO, vWf and exercise parameters
www.cardiologyjournal.org
Willebrand factor levels at the beginning of the
investigation were similar to those found after
4-week nebivolol treatment in groups 1 and 2.
The prolongation of exercise time, increase in
MET and decrease in double product were obse-
rved after nebivolol treatment in group 1. The si-
gnificantly longer exercise time, higher increase in
MET and higher double product were observed both
before and after nebivolol treatment in group 1, as
compared with group 2. The ST- segment depression
after nebivolol treatment in groups 1 and 2 was smal-
ler than that recorded before the onset of the investi-
gation. Unfortunately, the observed differences were
not statistically significant. However, the ST- segment
depression at peak exercise in group 1 was respecta-
bly smaller than that recorded in group 2.
The significant increase in serum NO concen-
trations after nebivolol treatment was accompanied
by a significant decrease in double product in gro-
ups 2 and 3 (Tables 2 and 3). Neither of the investi-
gated biochemical or electrocardiographic exerci-
se test parameters were changed significantly in
group 4.
A significant negative correlation between ba-
seline serum NO concentration and double product
calculated at peak exercise before the onset of ne-
bivolol treatment was found in all the examined
patients (R = 0.426; p < 0.03). A positive correla-
tion between plasma von Willebrand factor concen-
trations and total cholesterol levels both before and
after nebivolol treatment was observed in the study
group (R = 0.714; p < 0.01 and R = 0.848; p < 0.03).
A positive correlation between serum NO concen-
trations and exercise time was found in group 1 after
nebivolol treatment (R = 0.921; p < 0.02). A signi-
ficant positive correlation between serum NO
concentrations after nebivolol treatment and double
product calculated at peak exercise before nebivo-
lol treatment was also observed (R = 0.895;
p < 0.01).
Significant fluctuations in blood concentrations
of total cholesterol, LDL-cholesterol, HDL-chole-
sterol or triglycerides were not found. The echo-
cardiographic interrogation did not show any signi-
ficant change of left ventricular ejection fraction
(LVEF).
Discussion
The treatment of arterial hypertension and
ischemic heart disease with beta-blockers has been
a gold standard for many years. Intensive research
on novel beta-blockers with more and more unique
biochemical properties has contributed to the de-
velopment of three generations of these drugs. The
novel beta-blockers can be distinguished by vario-
us degrees of cardiac selectivity and vasodilating
properties. Nebivolol seems to be a promising tool
in the complex treatment of arterial hypertension,
ischemic heart disease and the prevention of athe-
rosclerosis, owing to it having specific vasodilating
properties and the highest cardiac selectivity among
Table 2. Concentration of serum nitric oxide, plasma von Willebrand factor versus exercise stress test
parameters in patients with arterial hypertension (group 1) and ischemic heart disease (group 2).
Investigated parameter Before nebivolol After nebivolol Statistical
treatment  treatment  significance
Group 1
von Willebrand factor (%)  105.9 ± 25.9 124.8 ± 53.4 NS
Nitric oxide [ng/ml] 10.9 ± 2.2 14.8 ± 6.5 < 0.05
Exercise time [min] 8.5 ± 1.7* 9.9 ± 1.1** < 0.05
Peak workload [MET] 8.4 ± 2.1* 9.7 ± 1.5* < 0.01
ST depression [mm] 3.5 ± 2.5 2.5 ± 2.0* NS
Double product [mm Hg × beats/min] 26815 ± 4737** 24284 ± 4156** < 0.05
Group 2
von Willebrand factor (%) 105.2 ± 18.6 123.9 ± 45.8 NS
Nitric oxide [ng/ml] 13.8 ± 6.1 16.3 ± 5.7 < 0.05
Exercise time [min] 5.5 ± 3.9 6.4 ± 2.5 NS
Peak workload [MET] 5.3 ± 3.6 5.8 ± 3.4 NS
ST depression [mm] 4.5 ± 2.6 4.0 ± 3.4 NS
Double product [mm Hg × beats/min] 20606 ± 4398 18800 ± 4331 < 0.05
*Statistically significant differences between analogous parameters in patients from groups 1 and 2 (p < 0.05); **statistically significant differences
between analogous parameters in patients from groups 1 and 2 (p < 0.01); NS — non-significant
166
Cardiology Journal 2008, Vol. 15, No. 2
www.cardiologyjournal.org
beta-blockers [8, 9]. The antiatherosclerotic effect
of nebivolol is closely associated with NO-media-
ted inhibition of LDL cholesterol-oxidation, con-
striction and proliferation of smooth muscle cells,
adhesion and aggregation of platelets, adhesion of
monocytes and favourable hemodynamic profile
despite an impaired endothelial function [10]. The
neutral effect on carbohydrate economy and the
renin-angiotensin-aldosterone system is another
clinically important property of nebivolol [11, 12].
On the other hand, NO demonstrates an immedia-
te effect on heart function, which is not fully under-
stood. The previous in-vitro investigations showed
both an inotropic positive and inotropic negative
effect of NO on the heart muscle [13, 14]. It was
even postulated that the inotropic effect of NO was
dependent on serum NO concentration, i.e. at lo-
wer serum concentrations, NO exerted an inotro-
pic positive effect, and at higher serum levels,
NO might have an inotropic negative effect on the
heart muscle [15]. There is also a lack of investiga-
tions on humans to elucidate fully the issue of ino-
tropic effects of NO on the heart. Rassaf et al. [16]
demonstrated in their recent investigation on he-
althy volunteers that the baseline serum NO con-
centration determined its beneficial effect on heart
function, manifested by the maintenance of optimal
stroke volume index.
Regarding the short follow-up of our study, we
decided to treat the selected parameters of electro-
cardiographic stress test as part of clinical observa-
tion. It must be stressed that ST-segment depres-
sion without concomitant anginal pain during exer-
cise tests in hypertensive patients with normal co-
ronary arteriogram results from dysfunction of
coronary microcirculation [17]. It is highly proba-
ble that the significant differences between groups
1 and 2 in the degree of ST-segment depression
during exercise tests are associated with ameliora-
tion of coronary microcirculation after nebivolol tre-
atment only in patients with arterial hypertension.
Galderisi et al. [18] demonstrated amelioration of
coronary flow reserve after 4-week nebivolol tre-
atment in hypertensive patients without ischemic
heart disease. Erdogan et al. [19] obtained similar
results in patients with idiopathic dilated cardiomy-
opathy. This can be related to a decrease in double
product just after 4-week nebivolol treatment, as
was demonstrated by our study.
It is very interesting that an increase in serum
NO concentration was observed after nebivolol tre-
atment in patients with increased double product
before the treatment protocol was started. More-
over, the positive correlation between the double
product, as calculated at peak exercise before ne-
bivolol protocol and serum NO concentration after
nebivolol treatment, was found in these patients.
These observations may give an incentive to fur-
ther investigations aimed at selecting patients who
will actually derive benefit from nebivolol treatment.
Table 3. Concentration of serum nitric oxide, plasma von Willebrand factor versus exercise stress
test parameters in patients with increase in serum nitric oxide concentration (group 3) and patients
without increase in serum nitric oxide concentration (group 4).
Investigated parameter Before nebivolol After nebivolol Statistical
treatment treatment significance
Group 3
von Willebrand factor (%) 106.5 ± 24.4 128.9 ± 53.8 NS
Nitric oxide [ng/ml] 12.3 ± 4.6 16.1 ± 6.2** < 0.05
Exercise time [min] 7.7 ± 2.7 8.6 ± 2.4 NS
Peak workload [MET] 7.5 ± 2.9 8.5 ± 2.4 NS
ST depression [mm] 4.1 ± 2.6 3.5 ± 2.7 NS
Double product [mm Hg × beats/min] 25999 ± 4510 21917 ± 2428 < 0.001
Group 4
von Willebrand factor (%) 101.2 ± 19.3 100.1 ± 12.8 NS
Nitric oxide [ng/ml] 11.8 ± 5.1 11.5 ± 5.0 NS
Exercise time [min] 9.0 ± 3.6 9.9 ± 3.2 NS
Peak workload [MET] 6.7 ± 3.2 7.2 ± 3.0 NS
ST depression [mm] 2.3 ± 2.0 2.0 ± 1.8 NS
Double product [mm Hg × beats/min] 20138 ± 3984 18997 ± 3012 NS
*Statistically significant differences between analogous parameters in patients from groups 1 and 2 (p < 0.05); **statistically significant differences
between analogous parameters in patients from groups 1 and 2 (p < 0.01); NS — non-significant
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It should be noted that an increase in systolic blood
pressure and heart rate at peak exercise, i.e.
an increase in double product, was found in
hypertensive patients with normal coronary arte-
ries. Consequently, it is obvious that the vasodila-
ting power of NO and beneficial effect of nebivolol
will be potentiated in this group of patients. On the
other hand, a significant increase in serum NO con-
centration, concomitant with a decrease in double
product after nebivolol treatment, was observed in
patients with ischemic heart disease (group 2),
whereas a positive correlation between double pro-
duct and serum NO concentration, as measured
before and after nebivolol administration, was con-
firmed in this group of investigated patients. Hen-
ce, it can be assumed that the presence of athero-
sclerotic foci in coronary arteries does not exclude
the meaningful effect of nebivolol on the vessel wall.
The previous investigations demonstrate that
the afore-mentioned pathophysiological changes do
not necessarily go together with the clinical status
of patients with ischemic heart disease. Chung et
al. [7] found significant changes in parameters of
endothelial function, including von Willebrand fac-
tor, angiogenesis and thrombogenesis factors
(VEGF, sFlt-1, TF), in patients with ischemic he-
art disease. However, these parameters did not
correlate with the severity of atherosclerosis in
coronary arteries. Yildirir et al. [20] investigated
other endothelial parameters and demonstrated that
E-selectin levels correlated with the severity of
atherosclerosis. However, statistical significance
was achieved only in patients with unstable angina
pectoris.
The documented contribution of von Wille-
brand factor to thrombus formation in acute myocar-
dial infarction also justifies further research on this
issue in patients with stable angina pectoris [21].
The positive correlation between plasma concen-
tration of von Willebrand factor and total choleste-
rol level, i.e. the fundamental risk factor for progres-
sion of atherosclerosis, was confirmed by our stu-
dy. The Edinburgh Artery Study was one of the first
studies to search for relationships between plasma
concentration of hemostatic and inflammatory mar-
kers and severity of atherosclerosis. The 12-year
follow-up demonstrated that inflammatory factors
are stronger risk factors for progression of athero-
sclerosis than the state of hypercoagulability [22].
These observations combined with our study re-
sults demonstrate that von Willebrand factor is
a generally accepted marker of vessel wall damage.
Nevertheless, the current stage of knowledge does
not allow connection to be made between fluctuations
in plasma concentration of von Willebrand factor and
clinical predictors of progression of ischemic heart
disease.
The investigation included quite a small group
of patients; therefore, it is more of a pilot study than
a thorough research study. Nonetheless, it gives an
incentive to more in-depth analysis and investiga-
tions on the effect of beta-blockers on the clinical
course of coronary artery disease.
Conclusions
We concluded that 4-week nebivolol treatment
ameliorates heart function as manifested by a de-
crease in double product, concomitant with an in-
crease in serum NO concentration. Nebivolol tre-
atment improves the parameters of electrocardio-
graphic exercise tests in patients with arterial
hypertension. No such improvement was observed
in patients without a significant increase in serum
NO concentration following nebivolol treatment.
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